
Macquarie initiates outperform rating on 4 Indian pharma stocks, sees 19-35% upside. Here's why
Indian pharma stocks: Macquarie Equity Research has initiated outperform ratings for Divi's Labs, Suven Pharma, Bluejet Healthcare, and Syngene. Among the 11 companies covered in the brokerage's regional Contract Development and Manufacturing …